Skip to content

Swiss Medical Weekly

ISSN 1424-3997

4 papers in the library · 276 citations · publishing 2007-2025

Papers

Sort Most recent Most cited

Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances

Swiss Medical Weekly July 1, 2025 Samuel E Christen, Elias Bekka, Yasmin Schmid et al. 3 citations

Psychoactive substances are compounds that can influence perception, consciousness, cognition, and emotions. The psychoactive substances caffeine, nicotine, cannabis, and psilocybin all originate from natural sources and can be used without complex processing or synthesis. Their natural availability has contributed to a long-standing history of human use and cultural significance. Caffeine and...

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Swiss Medical Weekly September 30, 2019 Felix Mller, Stefan Borgwardt 10 citations

Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s. Researchers were interested in the unique effects induced by this substance, some of which resemble symptoms seen in schizophrenia. Moreover, during that period LSD was studied and used for the treatment of several mental disorders such as...

Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling

Swiss Medical Weekly January 11, 2015 Matthias E. Liechti 188 citations

Novel psychoactive substances are newly used designer drugs ("internet drugs", "research chemicals", "legal highs") potentially posing similar health risks to classic illicit substances. Chemically, many novel psychoactive substances can be classified as phenethylamines, amphetamines, synthetic cathinones, piperazines, pipradrols/piperidines, aminoindanes benzofurans, and tryptamines....

Intravenous ketamine therapy in a patient with a treatment-resistant major depression

Swiss Medical Weekly April 21, 2007 Michael Liebrenz, Alain Borgeat, R Leisinger 75 citations

BACKGROUND: Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms. OBJECTIVE: To corroborate antidepressant effectiveness of IV ketamine in a patient with a co-occurring substance use disorder for the first time in a European...